Japanese technology investor SoftBank Group has launched a joint venture with Tempus AI that aims to leverage AI to analyze personal medical data to facilitate better treatment recommendations.

Tempus conducts genomic testing services and provides AI-informed treatment and clinical trial recommendations in the U.S., based on a database of millions of patients’ clinical records.

CEO Masayoshi Son stated in a Tokyo briefing that the firm hopes to bring Tempus’ service to Japan, making the country the only healthcare market outside of the US with such services.

“Working with Tempus, we’ll develop services at pace in Japan,” Son said. “With the database of 7.7 million U.S. patients, we’re at a running start.”

Additionally, Softbank stated that the parties are anticipated to each put 15 billion yen ($93 million) into the venture, which is expected to be finalized in July, subject to the fulfillment of closing conditions.